Eight of 15 patients who receive NG-01 therapy as spinal injection see better disability scores; inventors say therapy may ‘dramatically improve’ patients’ lives
A new Israeli stem cell therapy, intended to make the brain of multiple sclerosis sufferers “repair itself,” has shown promise in a small clinical trial, with several patients experiencing hopeful biological changes and reduced disability.
NeuroGenesis, a clinical-stage biopharmaceutical company, tested its personalized NG-01 therapy on patients, administering it in two different ways. An intravenous injection had some effect, but doctors observed particularly positive changes among patients who received an injection into the spinal cord fluid.
Of the 15 patients who received spinal injections, nine subsequently experienced a drop in levels of neurofilament light chain (NfL), a protein that is heightened among MS patients as disability progresses. In a control group that received placebo injections, only one of the 15 patients experienced such a drop.
Of the nine patients who received the therapy as a spinal injection and had reduced NfL levels, all but one went on to have improved disability scores, even 12 months later when the research finished. The study has been peer-reviewed and published in the journal Stem Cells Translational Medicine.
Continue reading… “Israeli study: Stem cells may help multiple sclerosis brain ‘repair itself’”
